CoChat

Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?

Open access

The DOI matches its Crossref record; 693 of the 711 references it cites were found in a registry or an index.

Abstract

Improving physical function and mobility in a continuously expanding elderly population emerges as a high priority of medicine today. Muscle mass, strength/power, and maximal exercise capacity are major determinants of physical function, and all decline with aging. This contributes to the incidence of frailty and disability observed in older men. Furthermore, it facilitates the accumulation of body fat and development of insulin resistance. Muscle adaptation to exercise is strongly influenced by anabolic endocrine hormones and local load-sensitive autocrine/paracrine growth factors. GH, IGF-I, and testosterone (T) are directly involved in muscle adaptation to exercise because they promote muscle protein synthesis, whereas T and locally expressed IGF-I have been reported to activate muscle stem cells. Although exercise programs improve physical function, in the long-term most older men fail to comply. The GH/IGF-I axis and T levels decline markedly with aging, whereas accumulating evidence supports their indispensable role in maintaining physical function integrity. Several studies have reported that the administration of T improves lean body mass and maximal voluntary strength in healthy older men. On the other hand, most studies have shown that administration of GH alone failed to improve muscle strength despite amelioration of the detrimental somatic changes of aging. Both GH and T are anabolic agents that promote muscle protein synthesis and hypertrophy but work through separate mechanisms, and the combined administration of GH and T, albeit in only a few studies, has resulted in greater efficacy than either hormone alone. Although it is clear that this combined approach is effective, this review concludes that further studies are needed to assess the long-term efficacy and safety of combined hormone replacement therapy in older men before the medical rationale of prescribing hormone replacement therapy for combating the sarcopenia of aging can be established.

Overview

Integrity signals

Registry

Crossref · 10.1210/er.2012-1002

Cites

693 of 693 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. Jorgensen, 1996, Substrate metabolism and insulin sensitivity following long-term growth hormone (GH) replacement therapy in GH-deficient adults, Endocrinol Metab, 3, 281
  2. Bjorntorp, 1997, Endocrine abnormalities in obesity, Diabetes Rev, 5, 52

Cited by

See all 156

Metadata

Authors
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P.
Affiliations
  • Consultant Endocrinologist (M.G.G.), Thessaloniki 54622, Greece;
  • King's College London (GB)
  • Mayo Clinic (US)
  • University of Surrey (GB)
  • St. Thomas' Hospital and King's College (P.S.), London SE1 7EW, United Kingdom; and Southampton University (P.S.), SO17 1BJ, Southampton, United Kingdom
Venue
Endocrine Reviews
Published
2012-03-20
Volume
33
Issue
3
Pages
314-377
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2163297196
Cited by
132
References
711
Citations by year
2026: 3 · 2025: 8 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 10 · 2020: 9 · 2019: 8 · 2018: 12 · 2017: 11 · 2016: 10 · 2015: 11 · 2014: 15 · 2013: 15 · 2012: 3
FWCI
1.93
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Open Research (University of Surrey) (submittedVersion)
  • Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK050456)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
Keywords
hormone replacement therapy, older men, physical function, sarcopenia, testosterone, growth hormone, insulin-like growth factor I, muscle strength, muscle mass, muscle protein synthesis, muscle stem cells, frailty, disability, insulin resistance
MeSH terms
Adult, Aged, Aged, 80 and over, Aging, Androgens, Body Composition, Drug Therapy, Combination, Humans, Insulin-Like Growth Factor I, Male, Middle Aged, Testosterone, Exercise, Muscle, Skeletal, Human Growth Hormone, Hormone Replacement Therapy, Muscle Strength, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.